Equity Offerings
-
-
-
-
-
-
-
Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
-
-
-
-
-
-
-
Summit Therapeutics posts Q2 loss, reports ivonescimab trial data
-
-
-
-
-
-
-
Summit Therapeutics sells antibiotic asset ridinilazole for up to $105M
-
-
-
-
-
-
-
Summit Therapeutics to present ivonescimab data at ELCC 2026
-
-
-
-
-
-
-
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Pos
-
-
-
-
-
-
-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Summit Therapeutics Raises $500 Million in Private Placement
-
13,334 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

